Anaptys Announces Participation in March Investor Conferences

Company Overview - AnaptysBio, Inc. is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases [2] - The lead program, rosnilimab, targets PD-1+ T cells and is currently in Phase 2b trials for rheumatoid arthritis and Phase 2 trials for ulcerative colitis [2] - Other antibodies in the portfolio include ANB033, a CD122 antagonist in Phase 1 trials, and ANB101, a BDCA2 modulator entering Phase 1 trials [2] - Anaptys has licensed multiple therapeutic antibodies to GSK for immuno-oncology, including a PD-1 antagonist (Jemperli) and a TIM-3 antagonist (cobolimab) [2] Upcoming Events - Daniel Faga, CEO of Anaptys, and other executive team members will participate in several investor conferences [1] - Conferences include TD Cowen 45th Annual Healthcare Conference in Boston, Leerink Partners 2025 Global Healthcare Conference in Miami, and Barclays 27th Annual Global Healthcare Conference in Miami [1] - Live webcasts of the events will be available on the Anaptys investor website, with replays accessible for at least 30 days [1] Event Schedule - Fireside chat and one-on-one investor meetings on March 4, 2025, at 1:10 PM ET / 10:10 AM PT [3] - Fireside chat and one-on-one investor meetings on March 11, 2025, at 10:40 AM ET / 7:40 AM PT [3] - Presentation and one-on-one investor meetings on March 12, 2025, at 8:30 AM ET / 5:30 AM PT [3]